Preclinical cardiovascular risk assessment in modern drug development.
Guth
Brian D
BD
Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co. KG, D-88397 Biberach an der Riss, Germany. brian.guth@bc.boehringer-ingelheim.com
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D015507:Drugs, Investigational / Q000378:metabolism / Q000633:toxicity*; D000072237:ERG1 Potassium Channel; D004594:Electrophysiology; D051638:Ether-A-Go-Go Potassium Channels / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D017408:Guidelines as Topic; D006329:Heart Conduction System / Q000166:cytology / Q000187:drug effects; D006352:Heart Ventricles / Q000166:cytology / Q000187:drug effects; D006801:Humans; D008564:Membrane Potentials / Q000187:drug effects; D023421:Models, Animal; D018408:Patch-Clamp Techniques; D018570:Risk Assessment
D015507:Drugs, Investigational; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels